INGN
Inogen, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.42
−0.55%Year over year
Reported trailing growth
- Revenue
- +3.2%
- EBITDA
- +25.2%
- EBIT
- +9.2%
- EPS
- +15.1%
- Free cash flow
- +56.7%
- Operating cash flow
- +70.3%
Forward estimates
Based on analyst estimates
- Revenue
- +2.2%
- EBITDA
- +81.6%
- EPS
- +35.0%
Three-year CAGR
- Revenue
- -2.6%
- EBITDA
- +82.4%
- EBIT
- +29.0%
- Net income
- +36.6%
- EPS
- +44.1%
- Free cash flow
- -93.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026